GRAIL, Inc. (GRAL) Reports Q2 Loss of $51.06/sh

GRAIL, Inc. (NASDAQ: GRAL) reported Q2 EPS of ($51.06), versus ($6.22) reported last year. Revenue for the quarter came in at $31.97 million, versus $22.41 million reported last year.

Strategic update:

Following a portfolio review, we are reducing our overall spend and focusing our resources on our core multi-cancer early detection ("MCED") priorities, including progress toward completion of our registrational studies and our premarket approval application submission.

As part of this restructure, we are reducing existing headcount and planned hires for 2024 by approximately 30% and substantially decreasing investment in product programs beyond Galleri. We are also reducing the size of our commercial organization, focusing our field-based activities on the most productive provider territories and streamlining investments in our enterprise business, which includes the Company's employer and life insurance businesses. In addition, we are making reductions in general and administrative expense to reflect the focus on our MCED opportunity. We will continue to invest in our biopharmaceutical partnerships, and are committed to working with our partners to leverage GRAIL's proprietary methylation technology in precision oncology applications.

We expect these cost reductions to extend our existing cash runway from the second half of 2026 into 2028. As a result, we anticipate reducing our burn in 2025 to $325 million. In 2024, we expect $27 million in savings, net of anticipated severance and benefits costs.

For earnings history and earnings-related data on GRAIL, Inc. (GRAL) click here.

You May Also Be Interested In

• Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office i
• Qualcomm (QCOM) Is Said To Near Deal For Ai Chip Startup Modular - Bloomberg
• A. O. Smith CEO Stephen Shafer named chairman